MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Guselkumab (TREMFYA®)

Selected References:

  • Anderson PO. 2021. Monoclonal antibodies during breastfeeding. Breastfeeding Medicine. 16(8): 591-93.
  • Dernoncourt A., et al. 2023. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 37(1), 73–87.
  • Kimball AB. 2020. Pregnancy outcomes in women exposed to guselkumab: Experience from the clinical development program. J Am Acad Dermatol. 83(6):AB27.
  • McMullan P et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update-Part I: Pregnancy. Journal of the American Academy of Dermatology.
  • Tremfya® Prescribing Information. Available online at http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed on May 28, 2024.
  • Wolfe C et al., 2024. A Retrospective Review of Pregnancies in our Psoriasis Biologics Cohort. Clinical and Experimental Dermatology. llae106.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.